Helix Biopharma
$0.17
12
+$0+0% Thursday 20:00
Statistics
Day High
0.14
Day Low
0.14
52W High
0.17
52W Low
0.14
Volume
287
Avg. Volume
59
Mkt Cap
40.74M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Earnings
1NovConfirmed
Expected EPS
N/A
Actual EPS
-0.0063
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HBPCF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.72B
Gilead Sciences
GILD
Mkt Cap90.4B
Merck &
MRK
Mkt Cap318.55B
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Pfizer
PFE
Mkt Cap169.83B
Novartis
NVS
Mkt Cap232.42B
Roche
RHHBY
Mkt Cap220.72B
Astrazeneca
AZN
Mkt Cap244.04B
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
About
Pharmaceuticals: Generic
Health Technology
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Show more...
CEO
Employees
9
Country
US
ISIN
US4229101096